FDA Approves Striverdi® Respimat® for the Treatment of COPD

FDA Approves Boehringer Ingelheim’s Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

Striverdi® Respimat® (olodaterol) Inhalation Spray 5 µg is a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in COPD patients, including chronic bronchitis and/or emphysema. It is a long-acting beta agonist (LABA) delivered via a propellant-free inhaler that generates a soft, slow-moving mist.

Since the active ingredient in STRIVERDI RESPIMAT is olodaterol, a long-acting beta agonist (LABA), it is not indicated to treat acute deteriorations of COPD and is not indicated to treat asthma. Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. All LABAs are contraindicated in patients with asthma without the use of a long-term asthma control medication.

More Info: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/08-01-14-fda-approves-boehringer-ingelheims-striverdi-respimat-olodaterol-inhalation-spray-maintenance-treatment-copd.html


Leave a Reply